Malignant Infantile osteopetrosis is also called as infantile autosomal recessive osteopetrosis. It is one of the rare skeletal dysplasia that is characterized using a radiographic pattern which shows increased bone density with involvement of the medullary portion. This type of disease typically manifests in infancy. Diagnosis of Malignant Infantile Osteopetrosis is based on radiographic evaluation and clinical evaluation, that is further confirmed using gene analysis technique if required. Due to medullary canal eradication and bony expansion, cranial nerve compression, grave pancytopenia, and fractures may ensue. It condition of the patient becomes more critical if untreated for a longer time period. Defect in one or more genes that are involved in functioning, formation and development of cells leads to osteopetrosis. This diseased condition involves some significant symptoms viz. blurring of vision, bone fractures, low blood cells level and recurrent dental infection.
The global Malignant Infantile Osteopetrosis Market is anticipated to register a significant CAGR over a forecast period. The increasing use of advanced diagnosis facilities such as DNA testing and bone marrow aspiration to diagnose the increasing prevalence of the osteopetrosis is the major factor, which anticipated to boost the growth of the global Malignant Infantile Osteopetrosis Market. The developing medical infrastructure and diagnostics facilities in the emerging markets such as China and India, also propel the growth of the global Malignant Infantile Osteopetrosis Market. The increasing research and development activities to bring the new diagnostic technologies and up-gradation, also expected to drives the global Malignant Infantile Osteopetrosis Market over a forecast period. The increasing discretionary funding by the various governments and institutes for the research activities, also expected to boost the global market of the malignant infantile osteoporosis treatment and diagnosis over the forecast period.
However, the higher cost associated with the diagnosis of the malignant infantile osteoporosis may hamper the diagnosis rate and restrain the growth of the global Malignant Infantile Osteopetrosis Market. The low awareness about the malignant infantile osteoporosis and unavailability of advanced treatment in poorly developed economies, may also hamper the growth of the global Malignant Infantile Osteopetrosis Market over a forecast period.
On the basis of regional presence, the global Malignant Infantile Osteopetrosis Market is segmented into five key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa.
Currently, North America is contributing the leading shares to the global Malignant Infantile Osteopetrosis Market in terms of value and anticipated to register a significant CAGR over a forecast period. The Europe is also contributing the moderate shares to the market due to the availability of advanced diagnostic technologies in the region and the reimbursement policies. APAC is the most lucrative market for the malignant infantile osteoporosis diagnosis and expected to show a robust growth to the market due to increasing awareness about the malignant infantile osteoporosis and developing medical infrastructure. MEA is at a nascent stage to the global Malignant Infantile Osteopetrosis Market and anticipated to register a decent growth to the market over a forecast period. Overall, the global Malignant Infantile Osteopetrosis Market is expected to show significant growth over a forecast period.
Some of the major market players in Malignant Infantile Osteopetrosis Market globally include GlaxoSmithKline plc., Pharmed Limited, Novartis International AG, Johnson & Johnson, Biocon Limited, InterMune, Inc., Pfizer Inc., Sanofi SA, Merck & Co., Inc. and many more.
A sample of this report is available upon request @